Atlas Trials

A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B

Clinical trial NCT01172392 · UNKNOWN

Trial details

NCT number
NCT01172392
Sponsor
ANRS, Emerging Infectious Diseases
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
Chronic Hepatitis BAgHbs Negativation
Start date
2011-01-01
Primary completion
2015-06-01
Enrollment
185

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.